Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

2683 - A phase I open label dose escalation trial evaluating VT1021 in patients with advanced solid tumors.


28 Sep 2019


Poster Display session 1


Clinical Research

Tumour Site


Wael Harb


Annals of Oncology (2019) 30 (suppl_5): v159-v193. 10.1093/annonc/mdz244


W. Harb1, A. Patnaik2, D. Mahalingam3, J. Liu4, P.Y. Wen5, G.I. Shapiro6, A.J. Bullock7, D. Juric8, L. Zheng9, K.N. Moore10, M. Patel11, R. Guttendorf12, S. Wang13, K. Kerstein13, G. Berk13, M.J. Cieslewicz13, J. Watnick13

Author affiliations

  • 1 Clinical, Horizon Oncology Center, 47905 - Lafayette/US
  • 2 Medical Oncology, South Texas Accelerated Research Therapeutics (START), 78229 - San Antonio/US
  • 3 Hematology And Oncology, Robert H Lurie Cancer Center, Northwestern University, 60611 - Chicago/US
  • 4 Gynecologic Oncology, Dana Farber Cancer Institute, 02215 - Boston/US
  • 5 Center For Neuro-oncology, Dana-Farber Cancer Institute, 02215 - Boston/US
  • 6 Medical Oncology, Dana Farber Cancer Institute, 02215 - Boston/US
  • 7 Gi Medical Oncology, Beth Israel Deaconess Medical Center, 02215 - Boston/US
  • 8 Oncology/hematology, Massachusetts General Hospital, 02114 - Boston/US
  • 9 Medical Oncology, Johns Hopkins Hospital, 21287 - Baltimore/US
  • 10 Gynecologic Cancers Clinic, Stephenson Cancer Center at the University of Oklahoma, 73104 - Oklahoma City/US
  • 11 Drug Development Unit, Florida Cancer Specialists, 34232 - Sarasota/US
  • 12 Research And Development, Aclairo Pharmaceutical Development Group, 22182 - Vienna/US
  • 13 Research And Development, Vigeo Therapeutics, 02140 - Cambridge/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2683


VT1021 is a cyclic pentapeptide that functions as a potent inducer of thrombospondin-1 (Tsp-1) expression in the tumor microenvironment (TME). By triggering the production of Tsp-1, VT1021 reprograms the TME from one that is immune-suppressive and tumor-promoting, to one that activates the adaptive immune system and is tumor-inhibiting. Tsp-1 reprograms the TME to: (i) induce apoptosis in tumor cells that express CD36 on their cell surface, (ii) convert macrophages from M2 to M1 polarization, which promotes phagocytosis and blunts immunosuppression, and (iii) inhibit angiogenesis. Preclinical studies have shown robust anti-tumor activities of VT1021 in animal models of ovarian, pancreatic and breast cancer, including complete tumor regression and reprogramming of the immune TME.


This study is a first-in-human, phase 1, open-label, multicenter dose escalation (Part 1) study with dose expansion (Part 2) in advanced solid tumors. The primary objectives are to assess the safety and tolerability of VT1021, assess dose-limiting toxicities (DLT), and determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D). Secondary objectives include the evaluation of pharmacokinetics (PK) and the pharmacodynamic (PD) effects of VT1021 in tumor biopsies, and assessment of preliminary efficacy.


In Part 1 of the study, 27 patients received 0.5-6.6 mg/kg of VT1021 twice weekly to determine the MTD and RP2D for expansion. One patient developed a grade 3 infusion reaction and 2 patients developed a grade 2 infusion reaction. Premedication with steroids and antihistamines has prevented subsequent significant infusion reactions. Other drug-related AEs included grade 1-2 fatigue, myalgia and dizziness. Dose proportionality was observed in PK analysis. Evidence of Tsp-1 expression, as measured by IHC on tumor biopsies, was observed. Prolonged stable disease was observed in 2 patients including ovarian and colorectal cancer. In Part 2 of the study, 75 patients will be enrolled based on tumor type and CD36 expression.


Through all doses tested thus far, VT1021 has been shown to be safe for patients and induces expression of Tsp-1.

Clinical trial identification

NCT03364400 December 6, 2017.

Editorial acknowledgement

Legal entity responsible for the study

Vigeo Therapeutics, Inc.


Vigeo Therapeutics, Inc.


S. Wang: Shareholder / Stockholder / Stock options, Full / Part-time employment: Vigeo Therapeutics, Inc. K. Kerstein: Full / Part-time employment: Vigeo Therapeutics, Inc. G. Berk: Advisory / Consultancy: Vigeo Therapeutics, Inc. M.J. Cieslewicz: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment: Vigeo Therapeutics. J. Watnick: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment, Officer / Board of Directors: Vigeo Therapeutics, Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.